QNRX VS SNGX Stock Comparison

Performance

QNRX
10/100

QNRX returned -81.93% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SNGX
10/100

SNGX returned -95.39% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

QNRX
29/100

QNRX receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

SNGX
25/100

SNGX receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

QNRX
10/100

QNRX has missed earnings 5 times in the last 20 quarters.

SNGX
10/100

SNGX has missed earnings 7 times in the last 20 quarters.

Profit

QNRX
10/100

Out of the last 14 quarters, QNRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SNGX
10/100

Out of the last 20 quarters, SNGX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

QNRX
35/100

QNRX has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.

SNGX
31/100

SNGX has had a lower than average amount of volatility over the last 12 months giving it a score of 30 of 100.

Analyst Price Targets

QNRX

"Analyst Price Targets" not found for QNRX

SNGX
75/100

3 analysts offer 12-month price targets for SNGX. Together, they have an average target of 0, the most optimistic target put SNGX at 0 within 12-months and the most pessimistic has SNGX at 0.

Sentiment

QNRX

"Sentiment" not found for QNRX

SNGX
58/100

SNGX had a bullish sentiment score of 57.60% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.00 comments, and 0.14 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Quoin Pharmaceuticals, Ltd. American Depositary Shares Summary

Nasdaq / QNRX

Healthcare

Biotechnology

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Soligenix, Inc. Common Stock Summary

Nasdaq / SNGX

Healthcare

Biotechnology

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Power up your portfolio